A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active Controlled Trial, Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension Over a 3-Month Period, Followed by a 12-Month Follow-Up With Open-Label DE-130A Treatment.
Latest Information Update: 30 May 2024
At a glance
- Drugs Latanoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Santen S.A.S.
- 07 May 2024 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial has been completed in Belgium (Global end date 26 Oct 2022), according to European Clinical Trials Database record
- 19 Dec 2022 This trial has been completed in Italy (Global end date 26 Oct 2022), according to European Clinical Trials Database record.